Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

BAM7

Catalog No: tcsc1453

Available Sizes

Size: 10mg

Size: 50mg

Specifications

CAS No:
331244-89-4

Formula:
$C_{21}H_{19}N_5O_2S$

Pathway:
Apoptosis

Target:
Bcl-2 Family

Purity / Grade:
>98%

Solubility:
DMSO : 5 mg/mL (12.33 mM; Need ultrasonic)

Observed Molecular Weight:
405.47

Product Description

BAM7 is a direct and selective activator of proapoptotic **BAX** with an **IC_{50}** of 3.3 μM.

IC50 & Target: IC50: 3.3 μM (BAX)[1]

In Vitro: BAM7 is selective for the BH3-binding site on BAX. BAM7 activates BAX and BAX-dependent cell death. Whereas treatment with BAX or BAM7 alone has no effect on the liposomes, the combination of BAM7 and BAX yields dose-responsive liposomal release

of entrapped fluorophore. BAM7 dose- and time-responsively impairs the viability of *Bak*$^{-/-}$ MEFs that exclusively express BAX but has no effect on *Bak*$^{-/-}$ MEFs that contain BAK but lack BAX. In contrast, standard proapoptotic stimuli such as serum withdrawal, Staurosporine and Etoposide induces an equivalent apoptotic response in *Bax*$^{-/-}$ and *Bak*$^{-/-}$ MEFs. As further evidence of BAM7 specificity of action, (i) BAM7 does not affect the viability of *Bax*$^{-/-}$ *Bak*$^{-/-}$ MEFs; (ii) ANA-BAM16, which does not bind or activate BAX, has no effect on *Bak*$^{-/-}$ MEFs; and (iii) BAM7 selectively induces cell death of *Bax*$^{-/-}$ *Bak*$^{-/-}$ MEFs reconstituted with wild-type BAX but not BAXK21E , which bears the mutation that abrogates BAM7 binding[1].